部門紹介

2018年

◆発表論文(英文)

<原著論文>

1.Kartagener syndrome complicated by immunoglobulin A nephropathy.
Oka K, Sugase T, Akimoto T, Murakami T, Nagayama I, Kaneko M, Asakura M, Ohara K, Saito O, Nagata D.
Int Med Case Rep J. 2018 Dec 10;11:359-362. doi: 10.2147/IMCRJ.S185887. eCollection 2018.

2.Multiple Sclerosis Drug Fingolimod Induces Thrombotic Microangiopathy in Deoxycorticosterone Acetate/Salt Hypertension.

  Iwazu Y, Muto S, Ioka T, Watanabe Y, Iwazu K, Kusano E, Nagata D.

  Hypertension. 2018 Sep;72(3):776-784

3. Shiga Toxin/Lipopolysaccharide Activates Caspase-4 and Gasdermin D to Trigger Mitochondrial Reactive Oxygen Species Upstream of the NLRP3 Inflammasome.
 Platnich JM, Chung H, Lau A, Sandall CF, Bondzi-Simpson A, Chen HM, Komada T, Trotman-Grant AC, Brandelli JR, Chun J,
 Beck PL, Philpott DJ, Girardin SE, Ho M, Johnson RP, MacDonald JA, Armstrong GD, Muruve DA.
 Cell Rep. 2018 Nov 6;25(6):1525-1536.e7.

4.
Unmasking a sustained negative effect of SGLT2 inhibition on body fluid volume in the rat.

  Masuda T, Watanabe Y, Fukuda K, Watanabe M, Onishi A, Ohara K, Imai T, Koepsell H, Muto S, Vallon V, Nagata D.
  Am J Physiol Renal Physiol. 2018 Sep 1;315(3):F653-F664.

5.Remission of nephrotic syndrome after surgical intervention for bronchogenic carcinoma: the 10-year follow-up of a patient with membranous nephropathy.

 Nagayama I, Akimoto T, Ono Y, Ueda Y, Nagata D.
Int Med Case Rep J. 2018 Jul 30;11:167-171. doi: 10.2147/IMCRJ.S170267. eCollection 2018.

6.Hemolytic Uremic Syndrome: An Increasingly Recognized Public Health Problem.

Murakami T, Akimoto T, Yamazaki T, Yoshizawa H, Okada M, Miki A, Nakagawa S, Ohara K, Sugase T, Masuda T, Kobayashi T, Saito O, Muto S, Nagata D.
Clin Med Insights Case Rep. 2018 Jul 3;11:1179547618785137. doi: 10.1177/1179547618785137. eCollection 2018.


7.Valacyclovir Neurotoxicity and Nephrotoxicity in an Elderly Patient Complicated by Hyponatremia.

Murakami T, Akimoto T, Okada M, Hishida E, Sugase T, Miki A, Kohara M, Yoshizawa H, Masuda T, Kobayashi T, Saito O, Muto S, Nagata D.
Drug Target Insights. 2018 Jun 25;12:1177392818782899. doi: 10.1177/1177392818782899. eCollection 2018.

8.Hypoglycemic Coma in a Hemodialysis Patient Receiving Blood Glucose-Lowering Therapy With the Single Agent Teneligliptin.
Minezumi T, Takeda SI, Igarashi Y, Sato K, Murakami Y, Nagata D.
Clin Med Insights Case Rep. 2018; 11: 1179547618763358.

9.Acquired von Willebrand Syndrome Complicating Nephrotic Syndrome: A Case of a Patient With Membranous  Nephropathy.
Sugase T, Akimoto T, Kimura T, Yagisawa T, Kusano E, Nagata D.
Clin Med Insights Case Rep. 2018

10.Renal immune surveillance and dipeptidase-1 contribute to contrast-induced acute kidney injury.
 Lau A, Chung H, Komada T, Platnich JM, Sandall CF, Choudhury SR, Chun J, Naumenko V, Surewaard BG, Nelson MC,          Ulke-Lemée A, Beck PL, Benediktsson H, Jevnikar AM, Snelgrove SL, Hickey MJ, Senger DL, James MT, Macdonald JA, Kubes P,   Jenne CN, Muruve DA.

 J Clin Invest. 2018 ;128:2894-2913.

11.Biological and Clinical Effects of Calciprotein Particles on Chronic Kidney Disease-Mineral and Bone Disorder.
  Akiyama K, Kimura T, Shiizaki K.
  Int J Endocrinol. 2018 Mar 27;2018.

12.A decreased soluble Klotho level with normal eGFR, FGF23, serum phosphate, and FEP in an ADPKD patient with enlarged kidneys due to multiple cysts
 Kanai T, Shiizaki K, Betsui H, Aoyagi J, Yamagata T.

 CEN Case Rep. 2018 Nov;7(2):259-263.

13.The impact of preserved Klotho gene expression on anti-oxidative stress activity in healthy kidney.

  Kimura T, Shiizaki K, Kurosu H, Akimoto T, Shinzato T, Shimizu T, Kurosawa A, Kubo T, Nanmoku K, Kuro-O M, Yagisawa T.
  Am J Physiol Renal Physiol. 2018;315:F345-F352.

14.Decline in estimated glomerular filtration rate is associated with risk of end-stage renal disease in type 2 diabetes with macroalbuminuria: an observational study from JDNCS.

Shimizu M, Furuichi K, Toyama T, Funamoto T, Kitajima S, Hara A, Ogawa D, Koya D, Ikeda K, Koshino Y, Kurokawa Y, Abe H,    Mori K, Nakayama M, Konishi Y, Samejima KI, Matsui M, Yamauchi H, Gohda T, Fukami K, Nagata D, Yamazaki H, Yuzawa Y,    Suzuki Y, Fujimoto S, Maruyama S, Kato S, Naito T, Yoshimura K, Yokoyama H, Wada T; Research Group of Diabetic          Nephropathy, the Ministry of Health, Labour, and Welfare of Japan and Japan Agency for Medical Research and Development.. Clin Exp Nephrol. 2018; 22: 377-387

15.Organic anion transporter OAT3 enhances the glucosuric effect of the SGLT2 inhibitor empagliflozin.
 Fu Y, Breljak D, Onishi A, Batz F, Patel R, Huang W, Song P, Freeman B, Mayoux E, Koepsell H, Anzai N, Nigam SK, Sabolić I, Vallon V
 Am J Physiol Renal Physiol. 2018;315:F386-F394.

 
16.Identification and quantification of plasma calciprotein particles with distinct physical properties in patients with chronic kidney disease.
Miura Y, Iwazu Y, Shiizaki K, Akimoto T, Kotani K, Kurabayashi M, Kurosu H, Kuro-O M.
Sci Rep. 2018; 8: 1256

17.Macrophage Uptake of Necrotic Cell DNA Activates the AIM2 Inflammasome to Regulate a Proinflammatory Phenotype in CKD.
 Komada T, Chung H, Lau A, Platnich JM, Beck PL, Benediktsson H, Duff HJ, Jenne CN, Muruve DA.
J Am Soc Nephrol. 2018; 29: 1165-1181.

 

発表論文(和文)

<原著>

1.自己血管内シャントに対するシャント血管マッサージの有用性に関する検討
 吉川友恵, 増田貴博,菅生太朗,小林玲子,松岡諒,山田恵子,笠野佳代子,齋藤修,長田太助

 
 日本透析医学会雑誌
2018;51 (5): 305-311

 
<総説>

1.【Q10 CVD発症抑制を目的とした場合のCKDステージG3b~5患者の降圧目標は、腎機能障害進行抑制を目的とした場合と同じですか?】
  岩津 好隆


  腎臓専門医のためのCKD診療Q&A2018;38-41


2.【Q11 RA系阻害薬はすべてのCKD患者に推奨されますか?
  増田 貴博


  腎臓専門医のためのCKD診療Q&A2018;42-44


3.【Q12 Ca拮抗薬が第一選択となるCKD患者の特徴を教えてください。】
  今井 利美


  腎臓専門医のためのCKD診療Q&A2018;45-47


4.【Q14 利尿薬はCKD患者の蛋白尿を減らすのですか?
  増田 貴博


  腎臓専門医のためのCKD診療Q&A2018;52-54


5.Q15 RA系阻害薬,Ca拮抗薬,利尿薬の3種の降圧薬を併用しても血圧が目標に達しない場合,次の選択肢を教えてください。】
  菱田 英里華, 長田 太助

  腎臓専門医のためのCKD診療Q&A2018;55-57


6."なぜ?""なに?"がサクッとわかる!新人スタッフのための血液透析患者の体のふしぎQ&A40~病態生理編~】
  合併症にまつわるQ&A 透析患者が溢水で呼吸が苦しくなるのはなぜ?どう予防・対処すればいい?(Q&A/特集)

  武島 えり, 長田 太助
   
  透析ケア
2018;24:443

 

7."なぜ?""なに?"がサクッとわかる!新人スタッフのための血液透析患者の体のふしぎQ&A40~病態生理編~】
  腎不全の病態にまつわるQ&A 透析患者に浮腫がみられるのはどうして?(Q&A/特集)

  武島 えり, 長田 太助

   透析ケア2018;24:403


8.【厳格な降圧療法の有効性と意義を熟考する】 末期腎不全進行阻止の観点からみた厳格降圧療法(解説/特集)
長田 太助

 血圧 2018; 25: 31-33.